3rd Annual Biosimilars Market Access Summit
The continued growth of the U.S. biosimilar market requires new strategies for market access for both biosimilars and biologics. The steady flow of approvals for biosimilar products, guidance on interchangeability, a solid track record of the first U.S. biosimilar, and the enactment of state substitution laws make 2017 the perfect time to adjust your market access strategy for both biosimilar and biologic drugs.
Call for Papers: Submit Abstract for Presentations
The World Congress 3rd Annual Biosimilars Market Access Summit is now accepting abstract submissions for 2017!
The deadline is December 22th 2016. Click here for details.
